Clinical trialNCT00545662TerminatedPhase 3Interventional

Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT)

SponsorEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Enrollment1,213Traumatic Brain Injury

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The Citicoline Brain Injury Treatment (COBRIT) is a randomized, double-blind, placebo controlled, multi-center trial of the effects of 90 days of citicoline on functional outcome in patients with complicated mild, moderate and severe traumatic brain injury.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Beth Ansel, PhD
National Institute of Child Health and Human Development, National Center for Medical Rehabilitation Research
Study Director
clinicaltrials.gov ↗
Howard Eisenberg, MD
University of Maryland, Baltimore
Principal Investigator
clinicaltrials.gov ↗
Jack Jallo, MD, PhD
Temple University
Principal Investigator
clinicaltrials.gov ↗
John Ward, MD
Virginia Commonwealth University
Principal Investigator
clinicaltrials.gov ↗
Joseph Ricker, PhD
University of Pittsburgh
Principal Investigator
clinicaltrials.gov ↗
Nancy Temkin, PhD
University of Washington
Principal Investigator
clinicaltrials.gov ↗
Ramon Diaz-Arrastia, MD, PhD
University of Texas Southwestern Medical Center
Principal Investigator
clinicaltrials.gov ↗
Shelly Timmons, MD, PhD
University of Tennessee Health Sciences Center
Principal Investigator
clinicaltrials.gov ↗
Sherry Melton, MD
University of Alabama at Birmingham
Principal Investigator
clinicaltrials.gov ↗
William Friedewald, MD
Columbia University Department of Biostatistics
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
University of Maryland, Baltimore
Baltimore, Maryland, United States
Temple University
Philadelphia, Pennsylvania, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
University of Tennessee Health Sciences Center
Memphis, Tennessee, United States
University of Texas, Southwestern Medical Center
Dallas, Texas, United States
Virginia Commonwealth University
Richmond, Virginia, United States
University of Washington
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboCiticoline

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jul 2007
Primary completion: 31 May 2011
Completion: 31 May 2011
Last update posted: 19 Dec 2012
Registered enrollment: 1,213
Registry id: NCT00545662

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.